Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked
Hansoh Pharmaceutical Group (HKG: 3692) released its interim results for the first half of 2026,...
Finanical Reports
HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%
China‑based HitGen Inc. (SHA: 688222) released its interim report for the first half of 2026,...
Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3
Insilico Medicine (HKG: 3696) released its interim results report for the six months ended June...
Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced its unaudited interim results for...
WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs
WuXi Biologics (HKG: 2269) announced its interim results for the six months ended 30 June...
Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its interim results for...
WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%
WuXi XDC (HKG: 2268) reported interim results for the first half of 2026 on Aug....
InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth
InnoCare Pharma Limited (HKG: 9969; SHA: 688428) reported interim results for the first half of...
Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%
Simcere Pharmaceutical (HKG: 2096) released its interim results for the first half of 2026, reporting...
Henlius H1 2026 Earnings: Trastuzumab Sales Surge 27.3% Revenue Growth as Overseas Profit Quadruples
Shanghai Henlius Biotech, Inc. (HKG: 2696) released its first-half 2026 results, reporting total revenue of...
Pharmaron Posts 17.9% First‑Half Revenue Growth as CRO Demand Rebounds; CDMO and All Core Segments Expand
Pharmaron Beijing Co., Ltd. (HKG: 3759), a leading integrated CRO and CDMO service provider, announced...
CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030
CARsgen Therapeutics (HKG: 2171) reported interim results for the first half of 2026, highlighted by...
Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth
Ascentage Pharma Group International (NASDAQ: AAPG; HKG: 6855) reported first‑half 2026 revenue of RMB 302...
Jiangsu Hengrui 1H 2026: Innovative Drug Sales Jump 16.4% to RMB 8.8 Billion, Offset Generic Drag as R&D Spending Climbs 19%
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) reported first‑half 2026 results showing total...
Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline
Gilead Sciences, Inc. (NASDAQ: GILD) announced second-quarter 2026 financial results with total revenues of USD...
Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook
Astellas Pharma Inc. (TYO: 4503) announced first-quarter fiscal year 2026 financial results featuring revenue of...
RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal
RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) released its performance forecast for the first half...
Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance
Eli Lilly and Company (NYSE: LLY) announced second-quarter 2026 financial results featuring revenue of USD...
BeOne Medicines Reports Record Q2 2026 Revenue of $1.7B, Driven by Brukinsa Growth and Raises Full-Year Guidance
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced Q2 2026 financial results featuring...
Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance
Merck & Co., Inc. (MSD; NYSE: MRK) reported financial results for the second quarter of...